By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-225-2860


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. or follow ARIAD on Twitter (@ARIADPharm).

Key Statistics

Ownership: Public

Web Site: Ariad
Symbol: ARIA

Company News
Bernie Sanders Demands Info on Ariad (ARIA)'s Leukemia Drug 10/21/2016 5:52:35 AM
How One Tweet From Bernie Sanders Sent Ariad (ARIA)'s Stock Plunging 10/17/2016 5:56:21 AM
How One Tweet From Bernie Sanders Sent Ariad (ARIA)'s Stock Plunging 10/17/2016 5:56:21 AM
Ariad (ARIA) Presents Updated Long-Term Follow-Up Results From The Phase 1/2 Trial On Investigational Drug Brigatinib At 2016 ESMO Meeting 10/10/2016 11:42:55 AM
How Struggling Ariad (ARIA) Used a Safety Problem to Quietly Raise Cancer Drug Price 10/7/2016 5:44:54 AM
Ariad (ARIA) Announces Regulatory Approval For Iclusig (Ponatinib) In Japan 9/28/2016 11:23:42 AM
Ariad (ARIA) Announces Ponatinib Data Presentations At European School Of Hematology Annual John Goldman Conference On Chronic Myeloid Leukemia 9/15/2016 10:55:59 AM
Ariad (ARIA) Completes Rolling Submission Of New Drug Application For Brigatinib To The FDA 8/30/2016 1:05:08 PM
Ariad (ARIA) To Present At The Morgan Stanley Global Healthcare Conference 8/29/2016 10:20:40 AM
PDL BioPharma (PDLI) Completes Second Tranche Payment Under Royalty Transaction With Ariad (ARIA) 8/2/2016 9:05:35 AM